Sort   by:  
 Page size 
UnknownBrain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy.
Brain microglia (MG) may serve as a human immunodeficiency virus 1 (HIV) reservoir and ignite rebound viremia following cessation of antiretroviral therapy (ART), but they have yet to be proven to harbor replication-competent HIV. Here, we isolated brain myeloid cells (BrMCs) from nonhuman primates ...
S-EPMC10266791 | biostudies-literature
UnknownVaried Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy.
Fourteen people with human immunodeficiency virus type 1 had longitudinal measurements of intact, defective, and total proviral DNA over the course of two decades of antiretroviral therapy. Three patterns of intact proviral DNA decay were revealed: (1) biphasic decline with markedly slower second-ph...
S-EPMC10474937 | biostudies-literature
UnknownSelective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.

Background

HIV-1 proviruses persist in people on antiretroviral therapy (ART) but most are defective and do not constitute a replication-competent reservoir. The decay of infected cells carrying intact compared with defective HIV-1 proviruses has not been well defined in people on ART.

Me...

S-EPMC7857155 | biostudies-literature
UnknownEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Background

Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the se...
S-EPMC7787219 | biostudies-literature
UnknownSafety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.

Background

Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal antibodies with an extended half-life.

Objective

To assess the safety and efficacy of amubarvimab plus romlusevimab.

Des...

S-EPMC10150320 | biostudies-literature
UnknownThe major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Infectious and inflammatory diseases have repeatedly shown strong genetic associations within the major histocompatibility complex (MHC); however, the basis for these associations remains elusive. To define host genetic effects on the outcome of a chronic viral infection, we performed genome-wide as...
S-EPMC3235490 | biostudies-literature
UnknownPost-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.

Background

It is unknown if early COVID-19 monoclonal antibody (mAb) therapy can reduce risk of Long COVID. The mAbs amubarvimab/romlusevimab were previously demonstrated to reduce risk of hospitalization/death by 79%. This study assessed the impact of amubarvimab/romlusevimab on late outcom...
S-EPMC11381616 | biostudies-literature
UnknownEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.

Background

NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (Covid-19) in phase 2b-3 trials in the United Kingdom and South Africa, but its efficacy had not yet been tested in ...
S-EPMC8693692 | biostudies-literature
Sort   by:  
 Page size